Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Ziprasidone is an atypical antipsychotic medication primarily utilized in the management of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. Chemically known as 5-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, its molecular formula is C22H27ClN4O2S. The substance is identified by the CAS Registry Number 114971-01-8. This compound functions as a potent antagonist at serotonin 5-HT2A receptors and dopamine D2 receptors, while also exhibiting significant affinity for alpha-1 adrenergic and histamine H1 receptors. Unlike many first-generation antipsychotics, Ziprasidone demonstrates a favorable side effect profile regarding metabolic disturbances, showing minimal impact on weight gain, blood glucose levels, and lipid profiles, making it a preferred option for patients concerned about metabolic syndrome.
The drug operates through a unique mechanism involving rapid dissociation from dopamine D2 receptors, which theoretically reduces the risk of extrapyramidal symptoms compared to typical antipsychotics. It is available in both oral capsule and intramuscular injection formulations, allowing for flexible treatment strategies in various clinical settings, including emergency situations requiring immediate stabilization. Clinical studies indicate that Ziprasidone effectively alleviates positive symptoms such as hallucinations and delusions, as well as negative symptoms like social withdrawal and emotional blunting. However, clinicians must monitor for potential cardiac risks, specifically QT interval prolongation, particularly when administered to patients with pre-existing heart conditions or those taking other medications that affect cardiac conduction. Despite these considerations, Ziprasidone remains a vital component in modern psychiatric pharmacotherapy, offering a balanced efficacy and tolerability profile for diverse patient populations suffering from severe mental health disorders. Its development marked a significant advancement in treating psychosis with reduced metabolic burden.